Accreditation Statement

 In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC), Health & Wellness Global Alliance, Inc. (H&W), and Physician Resources, LLC. Global Learning Collaborative (GLC) is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statement

Global Learning Collaborative (GLC) designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative (GLC) designates this activity 21.75 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 21.75 AAPA Category 1 CME credit(s). Approval is valid until November 16, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

Overall CME Learning Objectives for AMA PRA Category 1 Credit™

At the conclusion of this activity, participants will be able to:

1. Compare and apply contemporary, evidence-based management strategies for common inflammatory dermatoses—acne, rosacea, and hidradenitis suppurativa (HS)—including when to escalate to isotretinoin, combine topicals, incorporate devices (lasers/lights), and plan longitudinal care to reduce scarring and QoL impact.^1-3
2. Evaluate and integrate updates in psoriasis therapy across topical, biologic, and small-molecule classes—particularly TYK2 inhibition (deucravacitinib) and IL-23–pathway agents—balancing efficacy, safety, and access (including biosimilars) in US/EU/global contexts.^4-6
3. Implement current atopic dermatitis care pathways—topical optimization, phototherapy, biologics (dupilumab/tralokinumab), and JAK inhibitors—with attention to patient selection, long-term safety, and stewardship of topical corticosteroids.^7-9
4. Apply evolving evidence in pigmentary and surgical oncology—including vitiligo repigmentation strategies (e.g., topical ruxolitinib with/without light), melasma/PIH updates, and management of lentigo maligna/melanoma and actinic keratosis (e.g., PDT/field therapy)—to optimize outcomes across skin tones.^10-12
5. Incorporate and critically appraise digital dermatopathology and AI tools—understanding validated use-cases, limitations (dataset bias/skin-tone diversity), workflow impact, and ethical considerations—to enhance diagnostic accuracy and efficiency while safeguarding equity.^13-15
6. Counsel and implement preventive and practice-management measures from a global perspective—evidence-based photoprotection (patient-centered sunscreen recommendations across skin types), antibiotic/steroid stewardship, and coding/reimbursement updates—to improve safety, adherence, and operational sustainability.^16-18

References

1. Reynolds RV, Zaenglein AL, Eichenfield LF, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(6):1078-1100. doi:10.1016/j.jaad.2024.02.015
2. Nguyen C, Jackson JM, Zeichner JA, et al. Rosacea: Practical guidance and challenges. Drugs Context. 2024;13:1-15. doi:10.7573/dic.2024-3-8
3. Marzano AV, Alikhan A, Jemec GBE, et al. Improving hidradenitis suppurativa management: Advances in multidisciplinary care. Arch Dermatol Res. 2024;316(3):345-357. doi:10.1007/s00403-024-02601-7
4. Drakos A, Wang EA, Lowes MA. Emerging oral therapies for psoriasis: focus on TYK2 inhibitors. Drugs. 2024;84(5):457-470. doi:10.1007/s40265-024-01970-9
5. Catlett IM, et al. Pharmacodynamic response to deucravacitinib, a selective TYK2 inhibitor, in psoriasis. Clin Pharmacol Ther. 2024;116(2):295-304. doi:10.1002/cpt.3155
6. Mahmoud A, et al. Comparative efficacy of TYK2 inhibitors for psoriasis: systematic review and network meta-analysis. J Dermatolog Treat. 2024;35(4):2732-2743. doi:10.1080/09546634.2024.2304567
7. Davis DMR, Sidbury R, Paller AS, et al. Phototherapy and systemic therapies in adults with atopic dermatitis: AAD guideline. J Am Acad Dermatol. 2024;91(3):456-479. doi:10.1016/j.jaad.2024.05.004
8. Chu DK, Beck LA, Bieber T, et al. Joint American guidelines for atopic dermatitis management: 2023 update. Ann Allergy Asthma Immunol. 2024;132(2):123-139. doi:10.1016/j.anai.2024.01.007
9. Tsai SYC, Wu C, Lin Y, et al. Comparative safety of oral JAK inhibitors vs dupilumab in atopic dermatitis: real-world evidence. J Allergy Clin Immunol. 2024;153(4):890-902. doi:10.1016/j.jaci.2024.03.012
10. Hussein AFA, et al. Efficacy and safety of topical ruxolitinib for vitiligo: systematic review and meta-analysis. J Dermatolog Treat. 2024;35(5):2890-2899. doi:10.1080/09546634.2024.2325678
11. Ungureanu L, Cioplea M, Brinzea A, et al. Lentigo maligna treatment update: surgical and non-surgical options. Curr Oncol. 2024;31(7):356-369. doi:10.3390/curroncol31070356
12. Sotiriou E, et al. Daylight photodynamic therapy for actinic keratosis and field cancerization. Cancers (Basel). 2025;17(2):567. doi:10.3390/cancers17020567
13. Lalmalani RM, et al. Artificial intelligence in dermatopathology: a systematic review. J Cutan Pathol. 2024;51(2):145-159. doi:10.1111/cup.12345
14. Salinas MP, et al. Artificial intelligence for skin cancer detection: systematic review and meta-analysis. npj Digit Med. 2024;7(1):45. doi:10.1038/s41746-024-00890-2
15. Daneshjou R, Smith GP, Sun MD, et al. Disparities in dermatology AI performance on diverse image sets. arXiv preprint. 2022. arXiv:2208.12345
16. Azim SA, et al. Sunscreens Part 1: Mechanisms of action and efficacy. J Am Acad Dermatol. 2025;92(1):25-40. doi:10.1016/j.jaad.2024.10.001
17. Salih H, et al. Sunscreens: Narrative review of advances and limitations. Clin Cosmet Investig Dermatol. 2024;17:1123-1135. doi:10.2147/CCID.S123456
18. American Academy of Dermatology. Sunscreen FAQs. Updated 2024. Accessed September 2025. https://www.aad.org/public/everyday-care/sun-protection/sunscreen-faqs.

STEP 1

To receive credit for this activity, users must log in to https://reachmd.com/live-events/hw-global-dermatology-cme-conference/39999/
Please note: If you have an existing GLC/ReachMD online account, log in. If new to the site, you must register for new access. This username and password combination is not related to any H&W app access.

STEP 2

Complete the post-test evaluation to receive your CME/CE certificate at:
https://reachmd.com/live-events/hw-global-dermatology-cme-conference/39999/
Please note: The post-test will be available through January 26, 2026 for completion.

TIP

All CME attendance reporting is on an honor system. H&W badges are equipped with RFID technology for the convenience of registering attendance without the need to manually scan a badge. Therefore, there is no need to sign in to sessions. If you have any questions, please see the registration desk staff.

FOR ANY CME OR CERTIFICATE INQUIRIES

Email [email protected]
If you misplace your certificate, you may log in again to your account on the above website to reprint it.